drugset / Trial / NCT01180296

Oral Progesterone for Prevention of Preterm Birth

NCT01180296

Phase 3 Completed 36 enrolled Fetal Medicine Foundation
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate whether daily oral micronized progesterone is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.

Timeline

Start
2006-11
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 400 mg Oral

Indications

No indication recorded.